Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : PYNG Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Jack Rayfield who wrote (4083)	7/3/1999 12:25:00 PM
From: HotShot1	Read Replies (2) \| Respond to of 8117

Everyone: Does anyone know why Pyng hasn't conducted trials with the other major ambulance systems? Rural Metro is good, but there are a couple of huge systems that have been overlooked completely? Why? Will the exclusions hinder the company's chances of marketing the F.A.S.T. 1 to those systems in the future?

To: Jack Rayfield who wrote (4083)	7/3/1999 1:36:00 PM
From: Bernard Elbaum	Respond to of 8117

A primary concern in marketing the FAST1 is getting information out to potential users. The first reaction of many potential users may be to try the device on a pilot basis in small quantities, as did the sites participating in the field trials, or to wait until there is wider market experience with the device. Since the field trials have been successful, a high priority should be to make the data and experience widely available. Medical journal articles are the best route, but the time to publication is slow and uncertain. A refurbished web site could help fill the gap in the interim. A web site established, either by Pyng itself, or by independent emergency medical experts with Pyng subsidizing the cost, could serve as a clearinghouse for information on the FAST1. Such a web site could include the following links: Articles under Journal Submission: the full text of such articles could be posted Research Efforts Under way: Researchers could post summaries of their projects Locate Potential Research Collaborators: Researchers could post potential interests here Chat: Practitioners could chat about clinical experience with the FAST1. Potential users could chat with field trial users and obtain a first-hand account of their experience. Feedback to Pyng: Users could email problems and suggestions Dealing with State Regulations: how others got their state to allow the FAST1 First-Line Access? Users could debate the merits of FAST1 use for first-line access Literature: A bibliography could be posted, perhaps with text of most pertinent articles I should think such a web site could be constructed and maintained at modest cost. Pyng could routinely notify existing and potential users to consult and use the website. If Pyng wishes to keep some information secure, perhaps registration as medical personel and issuance of a password could be required. I'd like to hear from Pyng whether or not they view such a web site as a good idea, and if so, when they plan to construct one.